AORT

Artivion, Inc., formerly CryoLife, is a medical device company focused on aortic disease management and cardiac surgery. The company develops, manufactures, and distributes surgical implants, stent grafts, and biological tissue products for the treatment of aortic aneurysms, dissections, and other cardiovascular conditions. Artivion's product portfolio includes endovascular stent grafts, surgical grafts, on-X mechanical heart valves, and preserved human tissues for cardiac and vascular repair. The company serves cardiac surgeons, vascular surgeons, and interventional cardiologists globally through a direct sales force and distribution partnerships. Artivion addresses the significant and growing market for aortic repair, driven by aging populations, improved diagnostic capabilities, and the development of less invasive treatment options. Founded in 1984 and headquartered in Kennesaw, Georgia, Artivion has expanded through organic innovation and strategic acquisitions. The company benefits from the growing aortic treatment market, clinical evidence supporting its products, and the shift toward endovascular approaches in aortic disease management.